Direxion Daily S&P Biotech Bear 3X Shares Price & Performance (LABD)

The Direxion Daily S&P Biotech Bear 3X ETF (LABD) plunged 8.47% to $9.62 on Tuesday, extending its 10-day decline to 23%. Despite the downturn, technical indicators suggest potential for a rebound, with a wide trading range and high volatility expected. Short-term traders should remain cautious amid rapid price swings.12

Direxion’s leveraged biotech ETFs, LABU and LABD, continue to draw attention for their amplified daily moves. LABU has recently outperformed broader markets over two weeks, while LABD has lagged. Both funds, designed for sophisticated traders, track the S&P Biotechnology Index and are unsuitable for passive, long-term investors due to leverage risk.32

LABU and LABD, Direxion’s leveraged biotech ETFs, declared dividends for March 2025. LABU paid $0.10714 per share, while LABD distributed $0.05463. These payouts reflect the funds’ performance and structure, with LABU’s larger dividend aligning with its recent outperformance compared to LABD’s more modest return.24